Florbetaben F-18 (Neuraceq®) Injection Solution 1.4 to 135 mCi/mL, 50 mL in 1 multi-dose glass vial, Diagnostic-For Intravenous Use Only, Manufactured by SOFIE Co dba SOFIE, Dulles, VA 20166 for Life Molecular Imagining Ltd., NDC 54828-001-50
Published October 4, 2023 · Recall initiated: August 22, 2023
Summary
FDA records drug Class II recall D-1177-2023, published October 4, 2023 and initiated August 22, 2023. Recalling firm: Sofie Co dba Sofie; Status: Terminated; Reported quantity: 6 patient doses; Lot: Batch # FBBVA123082201, EOS: 22 Aug 2023/08:25, EXP: 22 Aug 2023/18:25. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).
What to do
Voluntary: Firm initiated · Telephone
Get an email if NEURACEQ has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- NEURACEQ
- Manufacturer
- Sofie Co dba Sofie
- Distributor
- Product was released to one facility in VA.
- Lot
- Batch # FBBVA123082201, EOS: 22 Aug 2023/08:25, EXP: 22 Aug 2023/18:25
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAEligard (leuprolide acetate) for injectable suspension, 7.5 mg every month, Sterile, Rx Only, Must beOctober 4, 2023
- FDAClearasil Rapid Rescue Deep Treatment Pads (Salicylic Acid 2%), packaged in 90-count plastic jar, furtherOctober 4, 2023
- FDACerebelly Smart Bar; Apple Kale flavor; 5 pk and 7 pk; ambient storageOctober 4, 2023
- FDAPerifix® / Epidural anesthesia set, medicatedSeptember 27, 2023
- FDAGallant VR Implantable Cardioverter Defibrillator: VR ICD REF CDVRA500Q Gallant DR Implantable CardioverterSeptember 27, 2023
- FDATyTek Tension Pneumothorax Access Kit TPAK 14 gauge 3.25 inch- Intended for introduction into the body toSeptember 27, 2023
Questions about this recall
Was Florbetaben F-18 (Neuraceq®) Injection Solution 1.4 to 135 mCi/mL, 50 mL in 1 multi-dose glass vial, Diagnostic-For Intravenous Use Only, Manufactured by SOFIE Co dba SOFIE, Dulles, VA 20166 for Life Molecular Imagining Ltd., NDC 54828-001-50 recalled?
Yes. FDA published recall D-1177-2023 on October 4, 2023. Reported hazard: Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).
What should I do if I have this product?
Voluntary: Firm initiated · Telephone
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: NEURACEQ.